Premium
Second‐generation antipsychotics show longer‐lasting benefits for cognition in schizophrenia
Publication year - 2019
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30458
Subject(s) - schizophrenia (object oriented programming) , cognition , medicine , drug , effects of sleep deprivation on cognitive performance , psychiatry , randomized controlled trial , cognitive impairment
A randomized trial evaluating two first‐generation antipsychotics and three second‐generation drugs has found that the newer drugs were more effective in reducing cognitive impairment in patients with schizophrenia. Although both classes of drug resulted in improvement in earlier stages of the study, the group receiving a first‐generation drug experienced worsening cognition by study endpoint, researchers reported.